Vivos Therapeutics Inc, which makes oral appliances for treating breathing-related sleep disorders, has expanded its portfolio with the addition of complementary, lower-cost products for treating conditions associated with obstructive sleep apnea.
The product line addition comes after Visos acquired patents and product rights from Advanced Facialdontics, a company holding propriety technology on certain FDA 510(k)-cleared dental and medical devices.
Advanced Facialdontics’ flagship product, the Preventive Oral Device, is a custom single-arch device with FDA clearance for treating an estimated 40 million patients in the US and Canada with temporomandibular joint dysfunction (TMD) and/or bruxism, both known to be closely associated with obstructive sleep apnea.
Advanced Facialdontics’ second cleared product, known as the Night Block, is a custom dual-arch mandibular advancement oral appliance that incorporates patented unilateral bite block technology, which can alleviate or eliminate many of the downsides of traditional oral appliance treatment, such as inflammation of the temporomandibular joint, facial pain, neck pain, headaches, tension, fatigue, clenching, and grinding.
The acquisition of the patents and product rights further enhances Vivos’ existing intellectual property and technology base, enabling Vivos to provide new, complementary products to many OSA patients who experience pain, discomfort, headaches, tooth loss, and other symptoms associated with TMD and bruxism, according to a press release by Vivos.
In addition, the acquisition will provide Vivos providers with an additional treatment option for patients who do not have obstructive sleep apnea but suffer from jaw pain, headaches, and daytime fatigue. Vivos expects to be able to manufacture the Advanced Facialdontics products through existing manufacturing relationships.
“TMD and bruxism are very common but often difficult to treat. We believe this highly effective technology from [Advanced Facialdontics] is a real breakthrough, with significant applications across many different kinds of existing oral appliances, such as clear aligners, palatal expanders, and traditional mandibular advancement devices, as well as our own CARE devices that are part of The Vivos Method,” says Kirk Huntsman, Vivos chairman and CEO, in a press release.
In connection with this transaction, Scott Simonetti, DDS, founder and CEO of Advanced Facialdontics and inventor of the acquired patents, has been appointed as Vivos’ senior director of research and product development.